230 related articles for article (PubMed ID: 20215543)
1. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
Kornblau SM; Singh N; Qiu Y; Chen W; Zhang N; Coombes KR
Clin Cancer Res; 2010 Mar; 16(6):1865-74. PubMed ID: 20215543
[TBL] [Abstract][Full Text] [Related]
2. [Expression of FoxO3a in patients with acute myeloid leukemia and its clinical significance].
Zhao JN; Lu QY; Niu XQ; Zhang P; Wang Z; Lin JZ; Zhuang YH; Lu JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):847-50. PubMed ID: 23998572
[TBL] [Abstract][Full Text] [Related]
3. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
Santamaría CM; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodriguez JN; Fernández-Abellán P; Bárez A; Peñarrubia MJ; Vidriales MB; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel JF; Gonzalez M
Leuk Res; 2009 Dec; 33(12):1706-9. PubMed ID: 19457552
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
[TBL] [Abstract][Full Text] [Related]
5. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
6. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
7. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia.
Sakoe Y; Sakoe K; Kirito K; Ozawa K; Komatsu N
Blood; 2010 May; 115(18):3787-95. PubMed ID: 20215638
[TBL] [Abstract][Full Text] [Related]
8. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.
Quintás-Cardama A; Zhang N; Qiu YH; Post S; Creighton CJ; Cortes J; Coombes KR; Kornblau SM
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):115-127.e15. PubMed ID: 25248926
[TBL] [Abstract][Full Text] [Related]
9. IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.
Chapuis N; Park S; Leotoing L; Tamburini J; Verdier F; Bardet V; Green AS; Willems L; Agou F; Ifrah N; Dreyfus F; Bismuth G; Baud V; Lacombe C; Mayeux P; Bouscary D
Blood; 2010 Nov; 116(20):4240-50. PubMed ID: 20671123
[TBL] [Abstract][Full Text] [Related]
10. [Study of thrombopoietin and its receptor C-mpl in acute leukemia].
Guo Y; Bian S; Luo M
Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):120-3. PubMed ID: 11601235
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
12. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
13. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
[TBL] [Abstract][Full Text] [Related]
14. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
15. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
Carter BZ; Qiu Y; Huang X; Diao L; Zhang N; Coombes KR; Mak DH; Konopleva M; Cortes J; Kantarjian HM; Mills GB; Andreeff M; Kornblau SM
Blood; 2012 Jul; 120(1):173-80. PubMed ID: 22645176
[TBL] [Abstract][Full Text] [Related]
16. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
Gale RE; Hills R; Kottaridis PD; Srirangan S; Wheatley K; Burnett AK; Linch DC
Blood; 2005 Nov; 106(10):3658-65. PubMed ID: 16076872
[TBL] [Abstract][Full Text] [Related]
17. Low expression of miR-204 is associated with expression of CD34 and poor performance status in denovo AML.
Abdelhafiz AS; Elsayed GM; Saber MM; Gameel A; Hamdy N
Int J Lab Hematol; 2020 Jun; 42(3):263-269. PubMed ID: 32048789
[TBL] [Abstract][Full Text] [Related]
18. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia.
Zhang W; Kornblau SM; Kobayashi T; Gambel A; Claxton D; Deisseroth AB
Clin Cancer Res; 1995 Sep; 1(9):1051-7. PubMed ID: 9816079
[TBL] [Abstract][Full Text] [Related]
19. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
20. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
